Biomarker for people at risk of colorectal cancer

New way to detect tumor biomarkers through a simple blood test

Breast cancer prognostic biomarker to improve chemotherapy decisions

Endo-rectal diagnostic tool for improved detection of prostate cancer

Current methods to diagnose prostate cancer (lat. Carcinoma) involve a combination of histologic examinations, prostate antigen testing, and digital rectal examinations. Histological examinations require invasive tissue biopsies, while prostate antigen testing and rectal examination are limited by detection and localization accuracy. As a result, these diagnostic methods to identify prostate cancer lack sensitivity, specificity, and convenience. There are currently, no available methods for accurately and non-invasively distinguishing malignant tumors from benign tissue in the prostate. Therefore, scientists including Andreas Helmut Hielscher, Hyun Keol Kim, Jong Hwan Michael Lee, and Emerson Lim at the Columbia University developed a technology that implements endo-rectal diffuse optical tomography (DOT) imaging to assess tumor localization, vascularity, and architecture for a more accurate detection and diagnosis of prostate cancer.

by
2018.10.16

Portable cancer test uses a smartphone: a new gold biosensor

Early diagnosis of cancer (lat. Carcinoma) greatly improves the odds of successful treatment. Yet many people, especially in developing countries, lack access to facilities to detect the disease. To address this issue, a research team at the University at Buffalo is creating a new cancer-spotting tool that health care providers could eventually use in areas that lack hospitals, clinics, and other treatment centers. This innovative tool is based upon a unique gold biosensor the research team created. When paired with a computer or smartphone and other inexpensive tools, the system is capable of spotting cancer biomarkers from a blood sample.

by
2018.10.16

The future of cancer detection test

The blood test to aid in early detection of lung cancer (lat. Carcinoma) using a combined panel of four biomarkers was developed by 20/20 GeneSystems. The company is focused on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development.  By leveraging this expertise and combining it with advanced machine learning and data analytics, new tests are being released which substantially improve the accuracy of biomarker blood tests for the early detection of cancers. This unique approach, being pioneered by 20/20,  results in affordable, highly accurate cancer blood tests. The company's innovative business model uses advanced analytics on large volumes of a real world, clinically relevant patient health data collected from hospital centers where tumor biomarker testing has been used for many years.

by
2018.10.15

Affordable Early Cancer Detection Blood Tests

Identifying sepsis-causing pathogens in 3 to 5 hours

NuMedii: drug discovery using big data and AI

Regular self-checks for skin cancer

The mobile app that allows to understand risk factors for skin cancer (lat. Carcinoma) and keep track of moles was developed by Skinvision. Skin cancer is the most common in Western countries. And the amount of patients is rapidly growing. The company embraces the idea that technology can take away the barriers that stand in the way of early detection of skin cancer, and get the patient to a doctor at the right time. Skin can change over time for many reasons, such as aging, genetic predisposition, exposure to sunlight, and allergies. Some skin changes may also be a sign of disease in the body. Skin diseases like skin cancer can grow slowly and go unnoticed easily, making it difficult for a person to keep track of any changes. The sooner person detects skin cancer, the higher the possibility of successful treatment and survival.

by
2018.10.12

Envisagenics discovers therapies to treat diseases caused by RNA splicing errors

Envisagenics was founded in 2014 as a spinoff of Cold Spring Harbor Laboratory. The company's mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Envisagenics focuses on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer (lat. Carcinoma) that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Envisagenics' breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence.

by
2018.10.12

The new standard for breast health exams

The next generation of medical image analysis for Mammography was developed by CureMetrix. The company is committed to the advancement of technology that will improve cancer (lat. Carcinoma) survival rates worldwide. Their research is focused on leveraging artificial intelligence and deep learning to develop the next generation of medical image analysis technology that radiologists and patients can confidently rely on. Today, they are honing powerful image analysis platform into an adjunct, precision tool for mammography. Their goal is to equip radiologists with the objective, data-driven answers they need to support patients and their healthcare team as they make decisions about breast cancer screening, treatment and diagnosis. CureMetrix believes that providing radiologists with the most advanced technology to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs and increased assurance that patients are getting the highest standard of care available from screening through post-biopsy follow-up.

by
2018.10.12

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

#1 VENTURE CLIENT PLATFORM